Latest news
Covid-19 nasal vaccine ready for clinical studies
Last week, Iconovo’s partner ISR received the reviewed and approved toxicology report that examined the company's vaccine for intranasal…
ICOpre trademarked in Japan
As part of Iconovos global commercialization plan, we are now strengthening our international IP portfolio by trademarking ICOpre in Japan.…
Press releases
Apr 04, 2023, 08:15
News
IR
English
Regulatory
MAR
Corporate Action
Other
Apr 04, 2023, 08:15
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
Mar 31, 2023, 10:01
News
IR
Swedish
Corporate Information
Other Corporate Information
Mar 16, 2023, 14:30
News
IR
Swedish
Regulatory
MAR
Corporate Information
Other Corporate Information
Feb 10, 2023, 11:20
News
IR
Swedish
Corporate Information
Other Corporate Information
Feb 09, 2023, 15:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Feb 08, 2023, 23:59
News
IR
English
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-disclaimer
Feb 08, 2023, 23:59
News
IR
Swedish
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-disclaimer
Feb 08, 2023, 17:32
News
IR
English
Regulatory
MAR
Report
Interim
Yearend
Feb 08, 2023, 17:32
News
IR
Swedish
Regulatory
MAR
Report
Interim
Yearend
Feb 08, 2023, 17:31
News
IR
Swedish
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-disclaimer
Feb 08, 2023, 17:31
News
IR
English
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-disclaimer
Feb 03, 2023, 08:30
News
IR
English
Corporate Information
Other Corporate Information
Feb 03, 2023, 08:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Jan 26, 2023, 08:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Jan 26, 2023, 08:30
News
IR
English
Corporate Information
Other Corporate Information
Jan 11, 2023, 08:40
News
IR
Swedish
Regulatory
MAR
Corporate Information
Other Corporate Information
Dec 15, 2022, 16:45
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Staff change
Dec 15, 2022, 16:45
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Staff change
Dec 07, 2022, 11:50
News
IR
English
Corporate Information
Other Corporate Information
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
Interim CEO
Anders Månsson
Mail: anders.mansson@iconovo.se